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Open access under CC BY-NC-ND license.Fig 1. Mycobacterium fortuitum infection associated with
acupoint embedding therapy. Multiple tender, erythema-
tous nodules with a linear distribution on the lower aspect
of right cheek and around the nasolabial fold.
Fig 2. Mycobacterium fortuitum infection associated with
acupoint embedding therapy. Acute mixed inflammation
composed of lymphocytes, neutrophils, and histiocytes
involving the entire dermis. (Hematoxylin-eosin stain;
original magnification: 3100).Infection with Mycobacterium fortuitum
during acupoint embedding therapy
To the Editor: Acupoint embedding therapy (AET),
also known as needle embedding therapy, embeds
absorbable foreign substances such as polydioxa-
none sutures in acupoints to achieve their long-term
stimulation. AET has been used to treat chronic and
painful disorders, particularly in traditional oriental
medicine,1 and is currently also used for aesthetic
purposes (eg, reducing facial wrinkles). However,
little is known about the adverse effects of this
therapy. Here, we report a patient with nontubercu-
lous mycobacteria (NTM) infection induced by AET.
A healthy 44-year-old woman presented with
multiple tender erythematous papules and nodules
on both cheeks (Fig 1). She had recently undergone
2 courses of AET separated by an interval of 1 month.
Needles were used to embed sterile polydioxanone
sutures in acupoints of lower aspects of both cheeks
and nasolabial folds. After the second course,
multiple oozing erythematous papules and tender
nodules appeared, the locations of which corres-
ponded with the points at which the sutures had
been embedded. The patient did not have a fever or
lymphadenopathy, and responded poorly to
acupuncture performed by the oriental medicine
doctors who performed the AET. The patient under-
went a 1-month course of combined minocycline
and cefixime therapy at another dermatology clinic.
A skin biopsy specimen revealed a dermal abscess
comprising lymphocytes, neutrophils, and histio-
cytes without foreign body granulomas or suture
materials (Fig 2). Dermal tissue culture revealed
atypical mycobacteria, which were identified as
Mycobacterium fortuitum by polymerase chain
reaction hybridization using the rpoB gene.
The isolate was susceptible to doxycycline,
ciprofloxacin, amikacin, and clarithromycin. The
patient responded well to combination therapy
with oral doxycycline, ciprofloxacin, and clarithro-
mycin. After 3 months of treatment, the lesions
continued to improve and a 6- to 12-month course
of combination therapy was recommended.
AET is thought to work by inducing the release of
neurochemicals in response to the application of
pressure or needles to acupoints.1 AET is increas-
ingly used for gradual face lifts and skin tightening,
especially among oriental medicine doctors inKorea. AET is advertised as a nonsurgical procedure
that uses natural materials; therefore, many patients
assume it is safer than filler or botulinum toxin
treatments. However, AET can cause iatrogenic
infections.
As with other strains of NTM, M fortuitum in-
fections are generally associated with the use of
contaminated solutions and/or equipment during
medical procedures. In the case presented here, the
source of contamination responsible for the NTM
infection could not be identified. However, because
disposable needles and threads were used, we
suspected that mycobacteria on the patient’s skin
may have been the source of the infection. The
patient was treated with minocycline, which might
have a lower benefit/risk ratio than doxycycline.2
Until the causative organisms are isolated, empirical
antibiotics should be used carefully.
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Letters e135There are reports of NTM infections being
contracted after tattooing3,4 and acupuncture.5
However, to our knowledge, this is the first reported
case of M fortuitum infection associated with AET.
Thus, practitioners should suspect mycobacterial
infection in patients presenting with nodules and
abscesses in areas that have been treated with AET.
Such infections should be treated promptly to
minimize further disfigurement.
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To the Editor: A 31-year-old woman was diagnosed
with a nonulcerated 2.01-mm deepmelanoma on her
left arm. She underwent wide excision with negative
surgical margins and a negative sentinel lymph node
biopsy. Sevenmonths later, she started having left hip
pain that became progressively worse. A noncontrastmagnetic resonance image revealed a large lesion in
her left proximal femur that was subsequently bio-
psied, confirming the diagnosis of metastatic mela-
noma. Subcutaneous lesions on her trunk and thighs
also developed. Biopsies revealed melanoma with
positive BRAF V600E mutation. She was started on
vemurafenib, a selective BRAF V600E inhibitor,1
dosed at 960 mg twice daily. After 3 weeks of
vemurafenib, she began receiving localized radio-
therapy to treat her femoral lesion. After 1 week of
daily radiotherapy, a brisk, raised, erythematous skin
reaction restricted to her left anterior and posterior
thigh developed. The erythematous regions were
confined to the areas where she was receiving
radiotherapy. With continuation of radiotherapy for
3 more days, an acute, rapidly worsening, and
extremely painful burning sensation developed in
her left anterior and posterior thigh. Physical exam-
ination revealed blistered and erythematous skinwith
dry andmoist desquamation in the radiotherapy fields
on her left anterior and posterior thigh, indicative of a
worsening skin reaction consistent with radiation
burns. She had received a total radiation dose of 30
Gy in 10 uninterrupted daily 3-Gy fractions as
originally planned. With discontinuation of radio-
therapy, her radiationdermatitis healed after 1month.
Two cases of localized radiation dermatitis that
resolved with topical corticosteroids and did not
require cessation of vemurafenib have been reported
in patients who started vemurafenib after completion
of radiotherapy.2 Another case of radiodermatitis was
reported in a patient receiving concomitant vemur-
afenib and radiotherapy who had been earlier
administered 60 Gy of local radiotherapy to the
same area that 4.5 years later developed radioderma-
titis upon administration of 20 Gy of radiotherapy.3
To our knowledge, our case represents the first
reported instance in the English literature of localized
radiation dermatitis developing in a patient receiving
concomitant vemurafenib and radiotherapy whowas
previously naive to both treatment modalities.
Sustained erythema seen in radiation dermatitis
typicallymanifests 10 to 14 days after dosing,whereas
sustained erythema developed in our patient after 7
days of radiotherapy. Moreover, the severity of the
radiation dermatitis seen in our patient after 10 days
of radiotherapy is not usually seen until after 4 to 5
weeks of radiotherapy at doses of 40 Gy or greater.
The radiosensitizing effect of vemurafenib leads to
increased cellular damage and impaired DNA repair.4
One proposed mechanism for radiosensitization sec-
ondary to vemurafenib suggests that vemurafenib
activates wild-type BRAF in keratinocytes and leads
to radiosensitization as a result.3 However, the exact
mechanism remains unclear. Dermatologists should
